Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease: A time-dependent analysis

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 7, 2013, Pages 715-720

  Ekström, Magnus P ^a,b   Hermansson, Anna Bornefalk ^c   Ström, Kerstin E ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b BLEKINGE HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic obstructive pulmonary disease; Comorbidity; Long term oxygen therapy; Survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; HUMANS; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SWEDEN;

EID: 84875821385     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201208-1565OC     Document Type: Article

References (48)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2011 [accessed 2012 Aug 29]. Available from http://www.goldcopd.org/
2. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-2107.
3. Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-2800.
4. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-969.
5. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-2560.
6. Mortensen EM, Copeland LA, Pugh MJV, Restrepo MI, de Molina RM, Nakashima B, Anzueto A. Impact of statins and ace inhibitors on mortality after COPD exacerbations. Respir Res 2009;10:45.
7. Short PM, Lipworth SIW, Elder DHJ, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2549.
8. Au DH, Bryson CL, Fan VS, Udris EM, Curtis JR, McDonell MB, Fihn SD. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004;117:925-931.
9. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-305.
10. van Gestel YRBM, Hoeks SE, Sin DD, Welten GMJM, Schouten O, Witteveen HJ, Simsek C, Stam H, Mertens FW, Bax JJ, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008;178:695-700.
11. Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-887.
12. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012;12:48.
13. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-283.
14. van Gestel YRBM, Hoeks SE, Sin DD, Simsek C, Welten GMJM, Schouten O, Stam H, Mertens FW, van Domburg RT, Poldermans D. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008;102:192-196.
15. Sheng X, Murphy MJ, MacDonald TM, Schembri S, Simpson W, Winter J, Winter JH, Wei L. Effect of statins on total cholesterol concentrations, cardiovascular morbidity, and all-cause mortality in chronic obstructive pulmonary disease: a population-based cohort study. Clin Ther 2012;34:374-384.
16. Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration 2010;80:3-7.
17. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-499.
18. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008;168:329-335.
19. Ekstrom MP, Wagner P, Strom KE. Trends in cause-specific mortality in oxygen-dependent chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:1032-1036.
20. Ekstrom MP, Hermansson AB, Strom KE. Effect of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease: a timedependent analysis [abstract]. Am J Respir CritCareMed 2012;185:A2263.
21. Strom K, Boe J. A national register for long-term oxygen therapy in chronic hypoxia: preliminary results. Eur Respir J 1988;1:952-958.
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
23. Swedish National Board of Health and Welfare. Quality and contents of the Swedish hospital discharge register. Stockholm: Swedish National Board of Health and Welfare. The Center for Epidemiology; 2008.
24. World Health Organization. Manual of the international statistical classification of diseases and health related problems. 10th revision. Geneva, Switzerland: World Health Organization; 1992.
25. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M. The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-735.
26. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011. Oslo: Norwegian Institute of Public Health; 2010.
27. Kleinbaum DG, Klein M. Extension of the Cox proportional hazards model for time-dependent variables. In: Kleinbaum DG, Klein M. Survival analysis, 2nd ed. New York: Springer-Verlag; 2005. pp. 211-256.
28. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
29. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950-1956.
30. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180: 948-955.
31. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
32. Strom BL, editor. Pharmacoepidemiology. West Sussex: John Wiley & Sons; 2005.
33. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
34. Bosco JLF, Silliman RA, Thwin SS, Geiger AM, Buist DSM, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 2010;63:64-74.
35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
36. LaRosa J, He J, Vupputuri S. Effect of statins on risk of coronary disease: meta-analysis of randomized controlled trials. JAMA 1999;282: 2340-2346.
37. Rutten FH, Cramer M-JM, Lammers J-WJ, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8:706-711.
38. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-1959.
39. Raupach T, Luthje L, Kogler H, Duve C, Schweda F, Hasenfuss G, Andreas S. Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model. Pulm Pharmacol Ther 2011; 24:215-220.
40. Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, Golbidi S, Churg AM. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011;183:50-58.
41. Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, Hruska N, Korber W, Buchner B, Criee CP, Hasenfuss G, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006;27:972-979.
42. Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby DE, Mills NL, MacNee W. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011; 66:769-774.
43. Strom K. Survival of patients with chronic obstructive pulmonary disease receiving long-term domiciliary oxygen therapy. Am Rev Respir Dis 1993;147:585-591.
44. Ringbaek TJ, Viskum K, Lange P. BMI and oral glucocorticoids as predictors of prognosis in COPD patients on long-term oxygen therapy. Chron Respir dis 2004;1:71-78.
45. Schols AM, Wesseling G, Kester AD, de Vries G, Mostert R, Slangen J, Wouters EF. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001;17: 337-342.
46. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;CD003566.
47. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJV. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol 2011;57:2127-2138.
48. Dorow P, Thalhofer S, Bethge H, Disselhoff G, Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 1990;16:S36-S44.